

Special Issue

Infections in Immunocompromised Hosts and Antimicrobial Therapy

Message from the Guest Editor

In recent years, the field of infectious diseases has received more attention, and there has been a growing awareness of the challenges posed by infections in immunocompromised individuals. We invite researchers from various disciplines to contribute their research results to this Special Issue. Potential topics of interest include, but are not limited to, the following:

- Mechanisms of susceptibility (the immunological factors contributing to increased infection risk in immunocompromised individuals);
- Novel diagnostic approaches (advancements in diagnostic methods specifically designed for the early and accurate detection of infections in this vulnerable group);
- Antimicrobial strategies (the efficacy and safety of antimicrobial agents in immunocompromised hosts, including considerations for drug interactions and adverse effects);
- Preventive measures (the prophylactic approaches used to minimize infection risk in individuals undergoing immunosuppressive therapies or organ transplantation);
- Clinical management (a discussion of experiences and best practices in the clinical management of infections, highlighting challenges and successful interventions).

Guest Editor

Dr. Antonio Riccardo Buonomo

Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples "Federico II", Naples, Italy

Deadline for manuscript submissions

closed (31 October 2024)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/182701

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)